Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.

Gregorc, V; De Braud, Fg; De Pas, Tm; Scalamogna, R; Citterio, G; Milani, A; Boselli, S; Catania, C; Donadoni, G; Rossoni, G; Ghio, D; Spitaleri, G; Ammannati, C; Colombi, S; CALIGARIS CAPPIO, Federico; Lambiase, A; Bordignon, Claudio